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Abstract
Rotator cuff tears can cause pain and weakness in the shoulder and affects a wide range of individuals. Conventional repair
consists of operative surgical techniques or conservative treatments including physiotherapy; however, there is still a big issue in
the increased risk of re-tearing of the tendons. Regenerative therapies are looking for new and novel ways of improving the
healing of tendon injuries. Platelet-rich plasma (PRP) uses the patient’s own blood in a concentrated form, to supply the repair site
with various growth factors that promote the healing response; however, research shows conflicting evidence about the efficacy
and effectiveness of PRP. Stem cell research is slowly increasing use of human patients in research trials and is showing
significant results in improving and reducing the re-tear rate. Tissue engineering encapsulates a range of techniques such as
scaffolds and patches to augment repair of the rotator cuff tendon, and research has shown that such techniques can provide
protection and assistance to the repairing tendon to improve results. This review aims to critically compare and evaluate recent
research and provide possible future directions.
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Introduction
The rotator cuff (Fig. 1) is a group of four muscles (the
supraspinatus, infraspinatus, teres minor, and subscapularis)
in the glenohumeral joint (GHJ). Rotator cuff tears (Fig. 1)
can cause pain and weakness in the shoulder. It is an injury
that plagues the general public (4% of under 40’s; 53% of over
60’s) and athletes alike [1]. Repair is often either non-opera-
tive, utilising physiotherapy to maintain range of movement,
rotator cuff, and deltoid strength, as well as scapula-stabilising
or operative, which employs surgical methods to repair and
reattach the tendon; however, it can lead to re-tearing, persis-
tent pain, and stiffness [2].
Classification of a rotator cuff injury is often based on the size
of the tear (Table 1) [2]. Healing rates are poor for surgical
repairs of large and massive tears. Novel techniques are looking
at enhancing the tendon tissue regeneration. Such techniques
include the use of platelet-rich plasma (PRP), a substance that
when injected releases various growth factors that play a role in
tissue repair; the use of stem cells, usually mesenchymal stem
cells (MSCs), which have the ability to self-renew and differen-
tiate to various tissues [3]; and the use of tissue-engineered ap-
proaches which use various scaffolds and patches to augment
repair [4, 5]. The aim of this review is to critically analyse the
new regenerative therapies that have been used recently to facil-
itate healing following rotator cuff injuries.
Novel Strategies Used in Rotator Cuff
Regeneration
Regenerative therapies utilised in rotator cuff regeneration all
differ in their application. PRP therapy is a form of
prolotherapy and requires patients to undergo injections, often
post-surgery; stem cell therapy requires the patient to undergo
surgery, with stem cells being applied following surgery; and
tissue engineering is a relatively new approach and covers a
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range of techniques, such as utilising scaffolds and patches to
augment surgery. PRP has predominantly been studied on
humans, although results are still not clear as there are numer-
ous contradictory findings. Stem cell research has been shown
to reduce the rate of re-tears, although there have currently
been limited studies on humans to date. Tissue engineering
is providing novel techniques with very promising results,
although not one ‘gold-standard’ has been determined for ro-
tator cuff repair. Research has used a variety of scores and
scales (Table 2) to assess quality of repair.
PRP has been utilised to augment surgical repair of medi-
um and large tears [6], resulting in a significantly improved
repair, as there was a significant improvement (decrease) in
the re-tear rate. Pandey et al. [7] investigated the use of PRP to
aid in the healing of large and massive rotator cuff repairs [7].
Similarly, a decreased re-tear rate was found 24 months post-
surgery for large tears, when compared to a control group of
50 patients. Results also demonstrated that PRP can reduce
pain and increase functionality, strength, and vascularisation
post-surgery.
Hernigou et al. [8] and more recently Kim et al. [9] have
provided the most comprehensive research when focusing on
stem cell therapy [8, 9], both indicating that stem cells can
improve rotator cuff surgery, especially improving
(decreasing) re-tear rates post-surgery, which is one of the
main concerns following surgical tendon repair. Any disrup-
tion (re-tear) in the initial healing stage can interfere with
rehabilitation strategies, resulting in a prolonged time frame
before patients can resume full activities (work or sport).
Tissue engineering approaches have utilised various scaf-
folds and patches to augment healing, such as ‘GraftJacket’
[10]. Results show that the use of this acellular human dermal
matrix augmentation can improve the quality of repair, as
more intact rotator cuffs were found (85% compared to
40%), as well as improving various scores on pain and func-
tion, compared to surgical repair with no additional
augmentation.
Critique of Techniques Used in Rotator Cuff
Regeneration
Platelet-Rich Plasma
Of all the regenerative techniques that will be critiqued in this
review, the use of platelets has been investigated in humans
more than studies in stem cell research and tissue-engineered
approaches. This could suggest that the use of platelets is
already becoming an accepted practice since it carries less
ethical issues.
Literature demonstrates (Table 3) that there are mixed,
sometimes, conflicting results, following the use of PRP.
Studies that adopted a human model reported a significant
improvement in scores (Table 2) such as the VAS, Constant-
Murley score, UCLA, and shoulder external rotation [6, 7, 13,
22]. When evaluating the actual injuries that were reported in
Fig. 1 Healthy anterior and
posterior views of the rotator cuff
muscles (left). Example of a
rotator cuff tear (supraspinatus)
(right)
Table 1 Classification of
rotator cuff tears by size Classification Tear size (cm)
Small < 1
Medium 1–3
Large 3–5
Massive > 5
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these studies, participants were only included if they had suf-
fered rotator cuff tears, whereas studies that reported no sig-
nificant differences often only looked at tendinopathy [11,
14]. This may suggest that PRP could be more effective in
the treatment of a full tear. Perhaps during tendinopathy, there
has already been some degree of healing, meaning that the
additional growth factors and stimulation PRP promotes are
not effective and can only help in the initial stages of ‘tendon-
bone’ formation.
This is verified by animal studies (rabbits and rats) that
created and repaired acute tears, where all results showed sig-
nificant improvement with the use of PRP. Improvements in-
cluded an increase in vascularisation and cellularity within
4 weeks [20] post-treatment and fibronectin production [19],
suggesting that PRP does benefit healing, however, only in the
initial stages. These studies used animal models (rabbits and
rats); thus, the results cannot be completely generalised to
humans.
Interestingly, there have been human studies that investi-
gated the use of platelet-rich fibrin (PRF) instead of the more
conventional PRP. Platelet-rich fibrin (or platelet-rich fibrin
matrix (PRFM)) is a variation of PRP and involves activation
of the fibrin-clotting cascade and a second centrifuge stage
[15]. As PRF is already formed into a matrix, it traps some
non-activated platelets, essentially delaying the release of
platelets and providing a longer time frame for platelet deliv-
ery. Yet again, results were varied, with Antuña et al. [23]
showing improvements whereas Rodeo et al. [15] and
Weber et al. [16] reported no significant differences to healing.
Although Antuña and colleagues (Antuña et al. [23]) did re-
port significant differences in shoulder function (constant
score increased) and pain scores (VAS decreased), their results
might not carry much statistical power as the population size
of their study was small (n = 28). These findings could suggest
that the use of PRF does not improve the healing of the
tendon-bone interface, perhaps due to gaps that are left behind
once the matrix has dissolved [15].
The majority of studies (animal models that found a signif-
icant improvement) reported an increase in the maximum load
to failure. This suggests that PRP can create a stronger ‘bond’
than that created naturally. This could be linked to the in-
creased vascularity reported earlier, as the repair site would
experience an increase in growth factors and inflammatory
cells to aid in the reparative and remodelling stages.
Stem Cells
When evaluating the use of stem cells (Table 4) in the
regenerative therapies of rotator cuff injuries, there are few
studies that have investigated the application of stem cells in
humans, although they have shown promising results. As
early as 2012, Gomes et al. found that an injection of
autologous bone marrow (BM) mononuclear cells following
surgery increased patient’s functional status [34]. However,
since there was no control group, results could only be com-
pared to histological data; since the study was not blinded,
there was the possibility of bias in the results; coupled with
small population size, the statistical relevance of these results
is questionable.
Of the three human studies included in this review, only
one did not use BM-derived MSCs. Kim et al. [9] utilised
adipose tissue (AT)–derived MSCs in combination with fibrin
glue, delivering mechanical aid whilst delivering MSCs. BM
is considered to be a favourable source of MSCs [35] and is
still being found to give the most beneficial effects in tendon
healing [36]. However, sourcing MSCs from AT is less pain-
ful, and there is a greater concentration of stem cells, which
would be desirable, as Hernigou et al. [8] alluded to. The
number of MSCs is important, since fewer MSCs included
in the applied solution may result in reduced tendon integrity,
which in turn could come full circle and result in a re-tear. The
study by Kim et al. [9] shows an alternative to BM as a source
for stem cells in the regenerative repair of the human rotator
cuff.
When comparing the animal studies that have used stem
cells to aid the healing, the majority have shown fairly positive
results, with only two studies finding no significant differ-
ences. Of these two, one was an early study [33, 37] which
included one of the shortest follow-up times of a maximum of
4 weeks, leaving the possibility that they might have
Table 2 Scores and scales used to
evaluate intervention
effectiveness
Score/Scale Measure Key points
Visual analogue scale (VAS) Pain Subjective, a 0–10 scale, patients mark the scale.
Constant-Murley score (constant) Functionality Subjective and objective. Four subscales: pain;
activities of daily living, strength, and range
of movement
University of California,
Los Angeles (UCLA)
Strength and function Subjective and objective. Measures, forward
elevation, strength, pain, satisfaction,
and function
American Shoulder and Elbow
Surgeons (ASES)
Pain and function Subjective and objective. Includes
physician-rated section. Measures pain,
function, and instability.
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overlooked any potential prolonged benefits. Further study
by Gulotta (2011a) looked at two different variations of
MSCs, demonstrating that there was no difference between
these variations. However, following the trend from other
research (Table 4), it would be wise to assume that there
would be some additional benefits in using MSCs than just
surgery alone.
It is possible to see (Table 4) animal studies show varying
degrees of success and analyse a range of different outcome
measures, for example maximum load at failure, cartilage
formation, and fat content. Kim et al. [9] suggested that
follow-up should be 12 months at least, as most re-tears hap-
pen within 6 months [35]. With the animal studies having a
short follow-up period and providing potentially subjective
histological analysis, data may be missing the requirements
for long-term recovery; however, more human trials would
need to look at these factors in similar time frames to confirm
that. Additionally, rehabilitation that humans undertake post-
surgery could pose as an added risk for re-tears.
Tissue Engineering
When examining the numerous tissue-engineering ap-
proaches in the regeneration of tissue, most have utilised
grafts and scaffolds, with most studies presented in this re-
view showing positive results (13 of 15 studies presented in
Table 5).
Autologous tenocyte implementation (ATI) is a novel
technique that has recently been used successfully in the treat-
ment of a rotator cuff tear and tendinopathy [47]. This was a
case study documenting a single participant; thus, it may not
carry much statistical power. Coupled with this, the partici-
pant had already undergone PRP, so there is the possibility
that healing, at least to some extent, had already occurred. As
ATI is an injection-based therapy, there is no need for surgery
which would require more time out and rehabilitation; it also
cancels out any chance of the repair re-tearing. As such, ATI
could provide an ethical alternative, as it uses autologous
tenocytes to create a healing response by utilising growth
factors, interleukins, and organised collagen fibres (Schwab
et al., [38]).
In 2016, Huegel et al. performed a similar, autologous
tendon–derived cell therapy on rats, and also added the use
of scaffold [43]. Results showed an increase in fibre organi-
sation, cellularity, and mechanical improvements which
could, to some extent, confirm results from Schwab and col-
leagues (Schwab et al. [38]). Interestingly, the use of autolo-
gous tendon cells could have a possible ‘age effect’. Results
in rats showed that it only worked in the young and old,
suggesting that there needs to be an imbalance in the tendon
(growing/ageing). The case study here was a 28-year-old
male, which poses the question: when does ageing start to
effect tendons?Ta
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Previous studies (Table 5) demonstrate that much of the
research that examines human models demonstrated signifi-
cant findings. However, there were no controls in five of the
studies [38–41, 47], which makes comparisons difficult since
they will have to be made via comparison of histological data,
giving room for different methodologies and techniques to
influence results. Although the findings show that shoulder
function has been improved, this could suggest that no matter
which engineering approached is used, shoulder function will
improve.
Two of the more popular augmentation devices used were
the ‘GraftJacket’ and the poly-L-lactic acid synthetic patch (or
‘x-repair’) [10, 39, 41, 42, 44]. GraftJacket worked in all but
one study; however, that particular instance used rat models,
whereas when used on human, it was found to significantly
improve the repair. It is perhaps more established, since it has
been used in surgeries since 2003 [39]. The ‘GraftJacket’ po-
tentially helps increase vascularisation at the repair site
through its structure and slowly dissolves once healing is com-
plete. The poly-L-lactic acid synthetic patch unanimously
found significant improvements with its use, although no con-
trol population was used, which does not rule out the possi-
bility of extraneous factors influencing healing; it acts in tan-
dem with the tendon whilst providing support and protection.
It is not possible to say which method is better right now;more
research is required including double-blinded, controlled stud-
ies. However, current findings suggest that as long as the patch
can help prevent the creation of scar tissue, which causes
weakness [5], then the augmentation has the chance to im-
prove rotator cuff tear.
This is verified when evaluating research conducted on
animals (Table 5), as most studies use different patches and
scaffolds, but all find improvements, whether it is failure load,
fibre organisation, vascularity, or even strength. Findings sug-
gest that additional assistance to the tendon during the initial
stages of healing, which prevents the accumulation of scar
tissue, makes for an overall better tendon repair.
Conclusion
Regenerative therapies have been focused on improving the
healing of the rotator cuff and decreasing the chance of re-
tears. Some techniques, such as PRP, have thus far been un-
able to present clear, concise findings and demonstrate an
ability to consistently and effectively improve the repair.
Stem cell research is showing positive results; however, more
work is required on human patients to be able to confidently
say this is the case; also, future work should look at the use of
adipose MSC’s as there are a few potential benefits to using
these, such as a less painful sourcing and a greater total con-
centration of MSCs available. Overall, tissue-engineering ap-
proaches appear to be the most effective at improving healing.
Future research needs to include more blinded and double-
blinded controlled studies with larger population sizes to,
again, be able to say that they will definitely result in an
improved rotator cuff repair.
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